CompletedNot Applicable

Neuroplasticity-Based Cognitive Remediation for Chemotherapy-Related Cognitive Impairment

United States21 participantsStarted 2020-02-17

Plain-language summary

The investigators propose to apply neuroplasticity-based computerized cognitive remediation (nCCR) to treat chemotherapy-related cognitive impairment (CRCI).

Who can participate

Age range35 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Be between 35 and 80 years of age,
✓. Have been diagnosed with noninvasive or invasive (Stage 1, 2, or 3A) breast cancer, colon cancer, lymphoma, endometrial cancer or ovarian cancer
✓. Have undergone treatment with systemic chemotherapy within the last 1-8 years,
✓. Endorse persistent CRCI subjective complaints (as defined below),
✓. Have no active cardiac, neurologic, or psychiatric illness,
✓. Fluent in and able to read English.

Exclusion criteria

✕. Any active neurologic psychiatric disease, clinically significant cognitive impairment or dementia, history of significant head trauma followed by persistent neurologic deficits, or known structural brain abnormalities,
✕. Current major depression or another major psychiatric disorder as described in DSM-5 (use of CNS active medications (e.g. antidepressants) will be permitted, provided dosing has been stable for at least 3 months),
✕. Any history of alcohol or substance abuse or dependence within the past 2 years (DSM-5 criteria),
✕. Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol.
✕. Use of any investigational drugs within 30 days or 5 half-lives, whichever is longer, prior to screening, and
✕. Use of cholinergic agents will be discouraged but will be reviewed on a case-by-case basis by the PI.
✕. Red-green color blindness. Other types of color blindness will be reviewed on a case-by-case basis by the PI.

What they're measuring

Evaluate completion rates of nCCR

Timeframe: 2 years

Evaluate visit frequency throughout nCCR treatment

Timeframe: through study completion, an average of 5 weeks.

Evaluate visit duration throughout nCCR treatment

Timeframe: through study completion, an average of 5 weeks.

Trial details

NCT IDNCT04230863

SponsorVanderbilt University Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-06-30

View on ClinicalTrials.gov More Cancer Survivors trials